Eravacycline Combination Therapy for MRAB

Inclusion Criteria: 1. ≥18 years old; 2. Meets the diagnostic criteria for pneumonia specified by the Chinese Medical Association Respiratory Branch. 3. CRAB is identified or predominant pathogenic bacteria, and drug sensitivity test indicates that Eravacycline is sensitive to the strain; 4. Patients expected to receive Eravacycline for ≥4 days; 5. Has already signed the informed consent Exclusion Criteria: 1. Pregnant or lactating; 2. Concurrent intracranial infection, urinary tract infection, or bloodstream infection; 3. Individuals in a moribund state; 4. The investigator believes there is any medical history, current condition, treatment, laboratory abnormalities, or other circumstances that may affect the trial results, interrupt the trial process (or the subject's inability to complete all trial requirements, operations, and visits), or increase the subject's risk with the experimental medication. Patients with terminal illnesses or evidence of immediately life-threatening diseases are excluded; 5. Patients with a history of allergic reactions to tetracyclines or any excipients in the investigational drug formulation